| Manchester Orthopedic Inc | |
| 365 Route 59, Ste 214, Airmont, New York 10952 | |
| (718) 929-2922 |
| Name | Manchester Orthopedic Inc |
|---|---|
| Organization Name | Manchester Orthopedic Inc |
| Location | 365 Route 59, Ste 214, Airmont, New York 10952 |
| Type | DME Supplier - Customized Equipment |
| Phone | (718) 929-2922 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
Duke University Medical Center researchers have discovered a new mechanism by which chronically high levels of the neurotransmitter dopamine exert their effects on the brain.
Using monoclonal antibodies to fight cancer is a complex, yet promising area of study. At Memorial Sloan Kettering Cancer Center, physician-scientists have focused their attention on expanding the current therapeutic antibody repertoire, and believe a newly developed platform will do just that - ultimately leading to new and innovative treatments for cancer patients with a broad range of malignancies.
U.S. residents ages 55 and older with annual incomes less than the federal poverty level are more likely to have disabilities that limit routine physical activities than those with higher incomes, according to a study published on Thursday in the New England Journal of Medicine, Bloomberg/Dallas Morning News reports.
Rich Pharmaceuticals, Inc. is pleased to announce that the Company has received approval from the U.S. Food and Drug Administration to commence its Phase 1/2 clinical for the treatment of Acute Myelocytic Leukemia (AML) and Myelodysplastic Syndrome (MDS) patients.
› Verified 4 days ago
| NPI Number | 1982881983 |
| Organization Name | MANCHESTER ORTHOPEDIC INC. |
| Type | DME Supplier - Customized Equipment |
| Address | 365 Route 59 Ste 214, Airmont, NY 10952 |
| Phone Number | 718-925-2922 |
News Archive
Duke University Medical Center researchers have discovered a new mechanism by which chronically high levels of the neurotransmitter dopamine exert their effects on the brain.
Using monoclonal antibodies to fight cancer is a complex, yet promising area of study. At Memorial Sloan Kettering Cancer Center, physician-scientists have focused their attention on expanding the current therapeutic antibody repertoire, and believe a newly developed platform will do just that - ultimately leading to new and innovative treatments for cancer patients with a broad range of malignancies.
U.S. residents ages 55 and older with annual incomes less than the federal poverty level are more likely to have disabilities that limit routine physical activities than those with higher incomes, according to a study published on Thursday in the New England Journal of Medicine, Bloomberg/Dallas Morning News reports.
Rich Pharmaceuticals, Inc. is pleased to announce that the Company has received approval from the U.S. Food and Drug Administration to commence its Phase 1/2 clinical for the treatment of Acute Myelocytic Leukemia (AML) and Myelodysplastic Syndrome (MDS) patients.
› Verified 4 days ago
News Archive
Duke University Medical Center researchers have discovered a new mechanism by which chronically high levels of the neurotransmitter dopamine exert their effects on the brain.
Using monoclonal antibodies to fight cancer is a complex, yet promising area of study. At Memorial Sloan Kettering Cancer Center, physician-scientists have focused their attention on expanding the current therapeutic antibody repertoire, and believe a newly developed platform will do just that - ultimately leading to new and innovative treatments for cancer patients with a broad range of malignancies.
U.S. residents ages 55 and older with annual incomes less than the federal poverty level are more likely to have disabilities that limit routine physical activities than those with higher incomes, according to a study published on Thursday in the New England Journal of Medicine, Bloomberg/Dallas Morning News reports.
Rich Pharmaceuticals, Inc. is pleased to announce that the Company has received approval from the U.S. Food and Drug Administration to commence its Phase 1/2 clinical for the treatment of Acute Myelocytic Leukemia (AML) and Myelodysplastic Syndrome (MDS) patients.
› Verified 4 days ago
Manchester Orthopedic Inc Type: DME Supplier - Customized Equipment Location: 365 Route 59, Airmont, New York 10952 Phone: (718) 929-2922 | |
Medical Comfort Type: Medicare Supplier Location: 421 Rt 9, Airmont, New York 10952 Phone: (845) 414-9994 |